Skip to content

Welcome to Discover Pharma! Today is : October 12, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

MaxCyte

  • Advanced Therapies,Clinical & Regulatory,Digital & Data,Genomics and sequencing

    MaxCyte launches off-target assays for adenine and cytosine base editors

    MaxCyte has launched two sequencing-based assays to identify potential off-target [...]

    August 19, 2026
  • Advanced Therapies,Drug Discovery & Development

    MaxCyte launches 96-well electroporation platform for cell therapy discovery

    MaxCyte, Inc. has launched ExPERT DTx, a 96-well electroporation platform [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development

    MaxCyte signs platform licence with Moonlight Bio to advance T cell therapies for solid tumours

    MaxCyte has entered a strategic platform licence with US biotech [...]

    May 5, 2026
  • Advanced Therapies,Manufacturing & Supply Chain

    MaxCyte and Ori Biotech integrate platforms to improve cell therapy manufacturing

    CD19 CAR CRISPR T cell workflow used to demonstrate shortened [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Novadip secures €10.4M to advance pivotal Phase 3 trial
    Categories: Advanced Therapies, Biotech & Pharma Business, Clinical & Regulatory, Research & Development, Therapeutic Areas
  • Telix to acquire ITM in $1.65BN radiopharmaceutical deal
    Categories: Biotech & Pharma Business, Manufacturing & Supply Chain, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Andelyn to manufacture FDA-approved Fayuvi gene therapy for Sanfilippo syndrome
    Categories: Advanced Therapies, Biotech & Pharma Business, Central Nervous System, Clinical & Regulatory, Manufacturing & Supply Chain, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top